NCT03971812: GLIOMANOID

Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma

Status unknown Last updated 13 June 2019

What this trial tests

trial testing Blood sample in Glioma in 20 participants. Status unknown.

Timeline

7 June 2019

Primary endpoint
6 December 2020

6 December 2020

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20
Start date	7 June 2019
Primary completion	6 December 2020
Estimated completion	6 December 2020
Sites	1 location across France

Drugs / interventions tested

• Blood sample — full drug profile →

Conditions studied

• Glioma — all drugs for Glioma →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs).

The working hypothesis is that 3D brain organoids can develop glioma-like structures and recapitulate phenotypic traits of gliomas when generated from hiPSCs expressing genetic mutants associated with glioma predisposition.

Methodology : To develop this pioneer study on the use of hiPSC-based brain organoids as a strategy to model gliomagenesis and study the impact of genetic mutants, it will be collect the peripheral blood mononuclear cell from 20 patients with high grade astrocytoma with or without IDH mutation. iPS will be generated from these PBMC and will be genetically modified according to different mutations. Then, it will be generate brain organoids according to standard protocols. Brain organoids generated from all different cells will be collected at different time points and analyzed for the presence of glioma-like structures and phenotypic hallmarks of gliomas.

From the proposed experiments, it will be expect that brain organoids will develop glioma-like features upon the presence of genetic mutations. Thus, it will be expect to demonstrate that brain organoids can be used as a reliable strategy to test the impact of genetic mutants, including the possible synergistic cooperation between different mutations on early gliomagenic events.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Organoids: The current status and biomedical applications.
   Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
2. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
   Zhou Z, Cong L, Cong X. · · 2021 · cited 112× · PMID 35036354 · DOI 10.3389/fonc.2021.762184
3. 3D bioprinting and its innovative approach for biomedical applications.
   Tripathi S, Mandal SS, Bauri S, Maiti P. · · 2023 · cited 82× · PMID 36582305 · DOI 10.1002/mco2.194
4. Applications of organoid technology to brain tumors.
   Wen J, Liu F, Cheng Q, Weygant N, et al · · 2023 · cited 26× · PMID 37248629 · DOI 10.1111/cns.14272
5. Cell Transdifferentiation and Reprogramming in Disease Modeling: Insights into the Neuronal and Cardiac Disease Models and Current Translational Strategies.
   Kalra RS, Dhanjal JK, Das M, Singh B, et al · · 2021 · cited 16× · PMID 34685537 · DOI 10.3390/cells10102558
6. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
   Chitrangi S, Vaity P, Jamdar A, Bhatt S. · · 2023 · cited 12× · PMID 37479967 · DOI 10.1186/s12885-023-11078-9
7. Neglected No More: Emerging Cellular Therapies in Traumatic Injury.
   Lowry LE, Herzig MC, Christy BA, Schäfer R, et al · · 2021 · cited 5× · PMID 33420590 · DOI 10.1007/s12015-020-10086-7
8. Cell reprogramming: methods, mechanisms and applications.
   Zhu F, Nie G. · · 2025 · cited 4× · PMID 40140235 · DOI 10.1186/s13619-025-00229-x